The inability of R-roscovitine to alter the expression of DR4 and DR5 was previously reported in a study by Kim et al. [34] and thus our investigations focused on the downstream signalling pathways elicited by the combination therapy of R-roscovitine and TRAIL in our TRAIL resistant GBM cells. This evidence concerns the gene TNFRSF10B and glioblastoma.